Physician profile
Amanda Dawn Small
NPI 1104290071
$14,254.68
in general payments reported to CMS, 2019-2025
61 companies · $2,833 in 2025
The $2,833 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,464 · 2022: $2,840 · 2023: $3,313 · 2024: $2,805 · 2025: $2,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,866 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,865.73 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,103.44 | 2021-2025 | |
| Novo Nordisk INC | $1,344.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,015.03 | 2021-2025 | |
| Glaxosmithkline, LLC. | $787.26 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $706.69 | 2021-2025 | Verquvo, Belsomra, Gardasil 9 |
| Lilly USA, LLC | $699.96 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $667.17 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $664.43 | 2021-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $604.18 | 2022-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.35 | 2021-2025 | Jardiance, Ofev |
| Abbott Laboratories | $455.66 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $433.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $322.44 | 2021-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $311.62 | 2022-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $286.40 | 2021-2025 | Trintellix |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.